USFDA Completes GMP Inspection at Dr. Reddy's Laboratories Facility; Form 483 Issued
Dr. Reddy's Laboratories Limited has reported that the United States Food & Drug Administration (USFDA) completed a Good Manufacturing Practices (GMP) inspection of its formulations manufacturing facility (FTO-3), located in Bachupally, Hyderabad.The inspection was conducted by USFDA between August 6, 2026, and August 14, 2026. Following the review, the company received a Form 483 which included four observations related to the facility.
Dr. Reddy's Laboratories Limited stated that it will address the issued observations within the stipulated timeline as mandated by the USFDA process.
DRREDDY Stock Price Movement
Shares of Dr. Reddy's Laboratories Limited slipped by 0.50% on Friday, settling at ₹1200 in market action. The stock traded through a tight session, with the shares finding support against a day low recorded at ₹1192.4.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.